Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type of Products & Services
3.2. Snippet by Technology
3.3. Snippet by Type of cancer
3.4. Snippet by End-user
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Technological Advancements In Drug Diagnosis And Services
4.1.1.2. Increasing Prevalence of Hematologic Cancer Globally
4.1.1.3. XX
4.1.2. Restraints
4.1.2.1. Unfavorable And Uncertain Reimbursement Scenario
4.1.2.2. XX
4.1.3. Opportunity
4.1.3.1. XX
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Before COVID-19 Scenario
6.1.2. Present COVID-19 Scenario
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type of Product & Service
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Product & Service
7.1.2. Market Attractiveness Index, By Type of Product & Service
7.2. Instruments
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Reagents & Consumables
7.4. Services
8. By Technology
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
8.1.2. Market Attractiveness Index, By Technology
8.2. PCR (Polymerase Chain Reaction) *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. IHC (immunohistochemical)
8.4. NGS (Next-Generation Sequencing)
8.5. Cytogenetics
8.6. Others
9. By Cancer Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.1.2. Market Attractiveness Index, By Cancer Type
9.2. Leukemia*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.2.3. Acute Myeloid Leukemia
9.2.4. Acute Lymphocytic Leukemia
9.2.5. Others
9.3. Lymphoma
9.4. Multiple myelomas
9.5. Others
10. By End-user
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
10.1.2. Market Attractiveness Index, By End-user
10.2. Clinical Laboratories*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Hospitals
10.4. Academic & Research Institutes
10.5. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Product & Service
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.6.1. Germany
11.3.6.2. UK
11.3.6.3. France
11.3.6.4. Italy
11.3.6.5. Russia
11.3.6.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.6.1. Brazil
11.4.6.2. Argentina
11.4.6.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.6.1. China
11.5.6.2. India
11.5.6.3. Japan
11.5.6.4. Australia
11.5.6.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. F. Hoffman-La Roche Ltd.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Abbott Laboratories
13.3. Qiagen N.V.
13.4. Thermo Fisher Scientific, Inc.
13.5. Illumina, Inc.
13.6. Bio-Rad Laboratories, Inc.
13.7. ICON PLC
13.8. Archerdx, Inc.
13.9. Invivoscribe, Inc.
13.10. Adaptive Biotechnologies
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us